Last reviewed · How we verify
NCT05805969
Accommodating Variable-Resistance Training in Patients With Juvenile Idiopathic Arthritis
NA trial testing Accommodating variable-resistance training in Juvenile Idiopathic Arthritis in 58 participants. Completed in 19 January 2023.
19 January 2023
Quick facts
| Lead sponsor | Cairo University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 58 |
| Start date | 28 November 2021 |
| Primary completion | 19 January 2023 |
| Estimated completion | 19 January 2023 |
| Sites | 1 location across Saudi Arabia |
Drugs / interventions tested
- Accommodating variable-resistance training
- Standard physical therapy
Conditions studied
- Juvenile Idiopathic Arthritis — all drugs for Juvenile Idiopathic Arthritis →
Sponsor
Cairo University
Who can join
Adults 12 to 18, any sex, with Juvenile Idiopathic Arthritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study was designed to investigate the effect of six weeks of accommodating variable-resistance training on muscle architecture, muscle strength, and functional performance in patients with juvenile idiopathic arthritis. Fifty-eight children with juvenile idiopathic arthritis were randomly allocated to the experimental group (n = 29, received the accommodating variable-resistance training) or the Control group (n = 29, received usual physical rehabilitation alone). Both groups were assessed for muscle architecture, muscle strength, and functional performance before and after treatment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Efficacy of accommodating variable-resistance training on muscle architecture, peak torque, and functional performance in patients with juvenile idiopathic arthritis: A randomized controlled trial.
Elnaggar RK, Azab AR, Alrawaili SM, Alhowimel AS, et al · · 2024 · cited 4× · PMID 38500984 · DOI 10.1016/j.heliyon.2024.e27693
Verify or expand the search:
- PubMed search for NCT05805969
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Juvenile Idiopathic Arthritis
Currently open trials in the same condition.
- NCT07243782 — Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cose · recruiting
- NCT05879419 — Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases · Phase 4 · active not recruiting
- NCT06007456 — Clinical, Laboratory and Ultrasound Stratification of Patients With Juvenile Idiopathic Arthritis · recruiting
- NCT03913962 — Health and Exercise Response in Children With Chronic and Auto-immune Pathologies · NA · recruiting
- NCT06560606 — UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease · recruiting
Other Cairo University trials
Trials by the same sponsor.
- NCT04155528 — Effect of Music Therapy on Postoperative Health Outcomes · NA · not yet recruiting
- NCT07363239 — CBCT-Based Safety Distance for Implant Placement Near the Inferior Alveolar Canal · not yet recruiting
- NCT07374575 — Egyptian Dental Professionals' Perspectives on the Oral Microbiome and Exosomes · not yet recruiting
- NCT07381153 — In-Vitro Cytotoxicity Assessment of INOX (Nanoksa G Plus) Polymer Discs · not yet recruiting
- NCT07375394 — 3D-Printed Extraoral Camera for Standardized Dental Photography · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05805969 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cairo University
- Last refreshed: 10 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05805969.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing